#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction to Tissue Engineering Scaffolds and Bottom-Up Fabrication
2-1	4-16	Introduction	abstract[2]	new[2]	_	_
2-2	17-19	to	abstract[2]	new[2]	_	_
2-3	20-26	Tissue	abstract[2]|object|object[5]	new[2]|new|new[5]	coref|coref|coref|coref	4-17|9-21[0_5]|4-17|9-21[0_5]
2-4	27-38	Engineering	abstract[2]|abstract|object[5]	new[2]|new|new[5]	coref	9-1[71_0]
2-5	39-48	Scaffolds	abstract[2]|object[5]	new[2]|new[5]	_	_
2-6	49-52	and	abstract[2]	new[2]	_	_
2-7	53-62	Bottom-Up	abstract[2]|abstract|object[7]	new[2]|new|new[7]	_	_
2-8	63-74	Fabrication	abstract[2]|object[7]	new[2]|new[7]	_	_

#Text=Traumas , diseases and population ageing are major reasons for damage and failure of human body tissues and organs , which require medical treatments for their restoration or replacement .
3-1	75-82	Traumas	abstract	new	_	_
3-2	83-84	,	_	_	_	_
3-3	85-93	diseases	abstract	new	_	_
3-4	94-97	and	_	_	_	_
3-5	98-108	population	abstract|abstract[11]	new|new[11]	coref|coref	3-8[12_11]|3-8[12_11]
3-6	109-115	ageing	abstract[11]	new[11]	_	_
3-7	116-119	are	_	_	_	_
3-8	120-125	major	abstract[12]	giv[12]	coref	8-2[63_12]
3-9	126-133	reasons	abstract[12]	giv[12]	_	_
3-10	134-137	for	abstract[12]	giv[12]	_	_
3-11	138-144	damage	abstract[12]|abstract	giv[12]|new	_	_
3-12	145-148	and	abstract[12]	giv[12]	_	_
3-13	149-156	failure	abstract[12]|event[14]	giv[12]|new[14]	_	_
3-14	157-159	of	abstract[12]|event[14]	giv[12]|new[14]	_	_
3-15	160-165	human	abstract[12]|event[14]|object[16]	giv[12]|new[14]|new[16]	coref	7-33[62_16]
3-16	166-170	body	abstract[12]|event[14]|object|object[16]	giv[12]|new[14]|new|new[16]	coref	4-4
3-17	171-178	tissues	abstract[12]|event[14]|object[16]	giv[12]|new[14]|new[16]	_	_
3-18	179-182	and	abstract[12]|event[14]	giv[12]|new[14]	_	_
3-19	183-189	organs	abstract[12]|event[14]|object	giv[12]|new[14]|new	coref	8-13
3-20	190-191	,	_	_	_	_
3-21	192-197	which	_	_	_	_
3-22	198-205	require	_	_	_	_
3-23	206-213	medical	abstract[18]	new[18]	ana	3-26[0_18]
3-24	214-224	treatments	abstract[18]	new[18]	_	_
3-25	225-228	for	_	_	_	_
3-26	229-234	their	abstract|event[20]	giv|new[20]	_	_
3-27	235-246	restoration	event[20]	new[20]	_	_
3-28	247-249	or	_	_	_	_
3-29	250-261	replacement	abstract	new	_	_
3-30	262-263	.	_	_	_	_

#Text=Despite the intrinsic body capability of repairing small injuries given sufficient time , to date , tissue growth in large ( centimeter-size ) defects requires complex , expensive and patient-painful autografts , allografts or xenografts .
4-1	264-271	Despite	_	_	_	_
4-2	272-275	the	abstract[23]	new[23]	_	_
4-3	276-285	intrinsic	abstract[23]	new[23]	_	_
4-4	286-290	body	organization|abstract[23]	giv|new[23]	coref	11-10
4-5	291-301	capability	abstract[23]	new[23]	_	_
4-6	302-304	of	_	_	_	_
4-7	305-314	repairing	_	_	_	_
4-8	315-320	small	abstract[24]	new[24]	_	_
4-9	321-329	injuries	abstract[24]	new[24]	_	_
4-10	330-335	given	_	_	_	_
4-11	336-346	sufficient	time[25]	new[25]	_	_
4-12	347-351	time	time[25]	new[25]	_	_
4-13	352-353	,	_	_	_	_
4-14	354-356	to	_	_	_	_
4-15	357-361	date	time	new	_	_
4-16	362-363	,	_	_	_	_
4-17	364-370	tissue	object|abstract[28]	giv|new[28]	coref|coref|coref|coref	7-17[58_0]|11-29[0_28]|7-17[58_0]|11-29[0_28]
4-18	371-377	growth	abstract[28]	new[28]	_	_
4-19	378-380	in	abstract[28]	new[28]	_	_
4-20	381-386	large	abstract[28]	new[28]	_	_
4-21	387-388	(	_	_	_	_
4-22	389-404	centimeter-size	abstract	new	_	_
4-23	405-406	)	_	_	_	_
4-24	407-414	defects	abstract	new	_	_
4-25	415-423	requires	_	_	_	_
4-26	424-431	complex	abstract[31]	new[31]	_	_
4-27	432-433	,	abstract[31]	new[31]	_	_
4-28	434-443	expensive	abstract[31]	new[31]	_	_
4-29	444-447	and	abstract[31]	new[31]	_	_
4-30	448-463	patient-painful	abstract[31]	new[31]	_	_
4-31	464-474	autografts	abstract[31]	new[31]	_	_
4-32	475-476	,	_	_	_	_
4-33	477-487	allografts	object	new	_	_
4-34	488-490	or	_	_	_	_
4-35	491-501	xenografts	abstract	new	_	_
4-36	502-503	.	_	_	_	_

#Text=In the case of bone , autograft and allograft implantation produces the best clinical results , but it requires secondary surgery and has a limited supply .
5-1	504-506	In	_	_	_	_
5-2	507-510	the	abstract[34]	new[34]	ana	5-18[0_34]
5-3	511-515	case	abstract[34]	new[34]	_	_
5-4	516-518	of	abstract[34]	new[34]	_	_
5-5	519-523	bone	abstract[34]|object	new[34]|new	_	_
5-6	524-525	,	_	_	_	_
5-7	526-535	autograft	event	new	_	_
5-8	536-539	and	_	_	_	_
5-9	540-549	allograft	object|event[38]	new|new[38]	coref|coref	6-20[0_38]|6-20[0_38]
5-10	550-562	implantation	event[38]	new[38]	_	_
5-11	563-571	produces	_	_	_	_
5-12	572-575	the	abstract[39]	new[39]	coref	6-19[50_39]
5-13	576-580	best	abstract[39]	new[39]	_	_
5-14	581-589	clinical	abstract[39]	new[39]	_	_
5-15	590-597	results	abstract[39]	new[39]	_	_
5-16	598-599	,	_	_	_	_
5-17	600-603	but	_	_	_	_
5-18	604-606	it	abstract	giv	_	_
5-19	607-615	requires	_	_	_	_
5-20	616-625	secondary	event[41]	new[41]	coref	6-15[48_41]
5-21	626-633	surgery	event[41]	new[41]	_	_
5-22	634-637	and	_	_	_	_
5-23	638-641	has	_	_	_	_
5-24	642-643	a	quantity[42]	new[42]	_	_
5-25	644-651	limited	quantity[42]	new[42]	_	_
5-26	652-658	supply	quantity[42]	new[42]	_	_
5-27	659-660	.	_	_	_	_

#Text=The main advantage of a xenograft is its abundant supply and no need for secondary surgery , but poor implantation results and problems of infection from donors are critical issues .
6-1	661-664	The	abstract[43]	new[43]	coref	6-8[46_43]
6-2	665-669	main	abstract[43]	new[43]	_	_
6-3	670-679	advantage	abstract[43]	new[43]	_	_
6-4	680-682	of	abstract[43]	new[43]	_	_
6-5	683-684	a	abstract[43]|object[44]	new[43]|new[44]	ana	6-8[0_44]
6-6	685-694	xenograft	abstract[43]|object[44]	new[43]|new[44]	_	_
6-7	695-697	is	_	_	_	_
6-8	698-701	its	object|abstract[46]	giv|giv[46]	_	_
6-9	702-710	abundant	abstract[46]	giv[46]	_	_
6-10	711-717	supply	abstract[46]	giv[46]	_	_
6-11	718-721	and	abstract[46]	giv[46]	_	_
6-12	722-724	no	abstract[46]|abstract[47]	giv[46]|new[47]	coref	19-26[183_47]
6-13	725-729	need	abstract[46]|abstract[47]	giv[46]|new[47]	_	_
6-14	730-733	for	abstract[46]|abstract[47]	giv[46]|new[47]	_	_
6-15	734-743	secondary	abstract[46]|abstract[47]|event[48]	giv[46]|new[47]|giv[48]	_	_
6-16	744-751	surgery	abstract[46]|abstract[47]|event[48]	giv[46]|new[47]|giv[48]	_	_
6-17	752-753	,	abstract[46]	giv[46]	_	_
6-18	754-757	but	abstract[46]	giv[46]	_	_
6-19	758-762	poor	abstract[46]|abstract[50]	giv[46]|giv[50]	_	_
6-20	763-775	implantation	abstract[46]|event|abstract[50]	giv[46]|giv|giv[50]	_	_
6-21	776-783	results	abstract[46]|abstract[50]	giv[46]|giv[50]	_	_
6-22	784-787	and	abstract[46]|abstract[50]	giv[46]|giv[50]	_	_
6-23	788-796	problems	abstract[46]|abstract[50]|abstract[51]	giv[46]|giv[50]|new[51]	coref	6-29[54_51]
6-24	797-799	of	abstract[46]|abstract[50]|abstract[51]	giv[46]|giv[50]|new[51]	_	_
6-25	800-809	infection	abstract[46]|abstract[50]|abstract[51]|event[52]	giv[46]|giv[50]|new[51]|new[52]	_	_
6-26	810-814	from	abstract[46]|abstract[50]|abstract[51]|event[52]	giv[46]|giv[50]|new[51]|new[52]	_	_
6-27	815-821	donors	abstract[46]|abstract[50]|abstract[51]|event[52]|person	giv[46]|giv[50]|new[51]|new[52]|new	_	_
6-28	822-825	are	abstract[46]	giv[46]	_	_
6-29	826-834	critical	abstract[46]|abstract[54]	giv[46]|giv[54]	_	_
6-30	835-841	issues	abstract[46]|abstract[54]	giv[46]|giv[54]	_	_
6-31	842-843	.	_	_	_	_

#Text=Besides , the neo-tissue generated within the interstitial spaces of these grafts is often different from the native tissue and requires large remodeling time for the complete biological and biomechanical integration with surrounding tissues .
7-1	844-851	Besides	_	_	_	_
7-2	852-853	,	_	_	_	_
7-3	854-857	the	substance[55]	new[55]	_	_
7-4	858-868	neo-tissue	substance[55]	new[55]	_	_
7-5	869-878	generated	_	_	_	_
7-6	879-885	within	_	_	_	_
7-7	886-889	the	abstract[56]	new[56]	_	_
7-8	890-902	interstitial	abstract[56]	new[56]	_	_
7-9	903-909	spaces	abstract[56]	new[56]	_	_
7-10	910-912	of	abstract[56]	new[56]	_	_
7-11	913-918	these	abstract[56]|object[57]	new[56]|new[57]	_	_
7-12	919-925	grafts	abstract[56]|object[57]	new[56]|new[57]	_	_
7-13	926-928	is	_	_	_	_
7-14	929-934	often	_	_	_	_
7-15	935-944	different	_	_	_	_
7-16	945-949	from	_	_	_	_
7-17	950-953	the	object[58]	giv[58]	coref	9-1[0_58]
7-18	954-960	native	object[58]	giv[58]	_	_
7-19	961-967	tissue	object[58]	giv[58]	_	_
7-20	968-971	and	_	_	_	_
7-21	972-980	requires	_	_	_	_
7-22	981-986	large	abstract[60]	new[60]	_	_
7-23	987-997	remodeling	event|abstract[60]	new|new[60]	_	_
7-24	998-1002	time	abstract[60]	new[60]	_	_
7-25	1003-1006	for	_	_	_	_
7-26	1007-1010	the	abstract[61]	new[61]	coref	12-25[105_61]
7-27	1011-1019	complete	abstract[61]	new[61]	_	_
7-28	1020-1030	biological	abstract[61]	new[61]	_	_
7-29	1031-1034	and	abstract[61]	new[61]	_	_
7-30	1035-1048	biomechanical	abstract[61]	new[61]	_	_
7-31	1049-1060	integration	abstract[61]	new[61]	_	_
7-32	1061-1065	with	abstract[61]	new[61]	_	_
7-33	1066-1077	surrounding	abstract[61]|object[62]	new[61]|giv[62]	coref	8-11[66_62]
7-34	1078-1085	tissues	abstract[61]|object[62]	new[61]|giv[62]	_	_
7-35	1086-1087	.	_	_	_	_

#Text=For these reasons , the development of novel solutions for tissues and organs bioengineering is extremely demanding in the medical field .
8-1	1088-1091	For	_	_	_	_
8-2	1092-1097	these	abstract[63]	giv[63]	_	_
8-3	1098-1105	reasons	abstract[63]	giv[63]	_	_
8-4	1106-1107	,	_	_	_	_
8-5	1108-1111	the	abstract[64]	new[64]	_	_
8-6	1112-1123	development	abstract[64]	new[64]	_	_
8-7	1124-1126	of	abstract[64]	new[64]	_	_
8-8	1127-1132	novel	abstract[64]|abstract[65]	new[64]|new[65]	_	_
8-9	1133-1142	solutions	abstract[64]|abstract[65]	new[64]|new[65]	_	_
8-10	1143-1146	for	abstract[64]|abstract[65]	new[64]|new[65]	_	_
8-11	1147-1154	tissues	abstract[64]|abstract[65]|object[66]	new[64]|new[65]|giv[66]	_	_
8-12	1155-1158	and	abstract[64]|abstract[65]|object[66]	new[64]|new[65]|giv[66]	_	_
8-13	1159-1165	organs	abstract[64]|abstract[65]|object[66]|object	new[64]|new[65]|giv[66]|giv	coref	9-38
8-14	1166-1180	bioengineering	abstract[64]|abstract[65]|object[66]|person	new[64]|new[65]|giv[66]|new	_	_
8-15	1181-1183	is	_	_	_	_
8-16	1184-1193	extremely	_	_	_	_
8-17	1194-1203	demanding	_	_	_	_
8-18	1204-1206	in	_	_	_	_
8-19	1207-1210	the	abstract[69]	new[69]	_	_
8-20	1211-1218	medical	abstract[69]	new[69]	_	_
8-21	1219-1224	field	abstract[69]	new[69]	_	_
8-22	1225-1226	.	_	_	_	_

#Text=Tissue engineering ( TE ) , an important biomedical engineering field , aims to solve this important challenge by combining scaffolds and bioactive molecules for the artificial reconstruction of functional , three-dimensional ( 3D ) tissues and organs .
9-1	1227-1233	Tissue	object|abstract[71]	giv|giv[71]	appos|coref|appos|coref	9-4[0_71]|10-15|9-4[0_71]|10-15
9-2	1234-1245	engineering	abstract[71]	giv[71]	_	_
9-3	1246-1247	(	_	_	_	_
9-4	1248-1250	TE	abstract	giv	appos	9-7[73_0]
9-5	1251-1252	)	_	_	_	_
9-6	1253-1254	,	_	_	_	_
9-7	1255-1257	an	abstract[73]	giv[73]	coref	21-23[212_73]
9-8	1258-1267	important	abstract[73]	giv[73]	_	_
9-9	1268-1278	biomedical	abstract[73]	giv[73]	_	_
9-10	1279-1290	engineering	abstract[73]	giv[73]	_	_
9-11	1291-1296	field	abstract[73]	giv[73]	_	_
9-12	1297-1298	,	_	_	_	_
9-13	1299-1303	aims	_	_	_	_
9-14	1304-1306	to	_	_	_	_
9-15	1307-1312	solve	_	_	_	_
9-16	1313-1317	this	abstract[74]	new[74]	_	_
9-17	1318-1327	important	abstract[74]	new[74]	_	_
9-18	1328-1337	challenge	abstract[74]	new[74]	_	_
9-19	1338-1340	by	_	_	_	_
9-20	1341-1350	combining	_	_	_	_
9-21	1351-1360	scaffolds	object	giv	coref	10-1[82_0]
9-22	1361-1364	and	_	_	_	_
9-23	1365-1374	bioactive	substance[76]	new[76]	coref	11-21[93_76]
9-24	1375-1384	molecules	substance[76]	new[76]	_	_
9-25	1385-1388	for	_	_	_	_
9-26	1389-1392	the	abstract[77]	new[77]	_	_
9-27	1393-1403	artificial	abstract[77]	new[77]	_	_
9-28	1404-1418	reconstruction	abstract[77]	new[77]	_	_
9-29	1419-1421	of	abstract[77]	new[77]	_	_
9-30	1422-1432	functional	abstract[77]|object[79]|object[80]	new[77]|new[79]|new[80]	coref|coref|coref|coref	12-19[103_79]|15-5[125_80]|12-19[103_79]|15-5[125_80]
9-31	1433-1434	,	abstract[77]|object[79]|object[80]	new[77]|new[79]|new[80]	_	_
9-32	1435-1452	three-dimensional	abstract[77]|object[79]|object[80]	new[77]|new[79]|new[80]	_	_
9-33	1453-1454	(	abstract[77]|object[79]|object[80]	new[77]|new[79]|new[80]	_	_
9-34	1455-1457	3D	abstract[77]|abstract|object[79]|object[80]	new[77]|new|new[79]|new[80]	coref	14-15
9-35	1458-1459	)	abstract[77]|object[79]|object[80]	new[77]|new[79]|new[80]	_	_
9-36	1460-1467	tissues	abstract[77]|object[79]|object[80]	new[77]|new[79]|new[80]	_	_
9-37	1468-1471	and	abstract[77]|object[80]	new[77]|new[80]	_	_
9-38	1472-1478	organs	abstract[77]|object[80]|object	new[77]|new[80]|giv	coref	15-8
9-39	1479-1480	.	_	_	_	_

#Text=Biomedical scaffolds are porous , implantable biomaterials , shaped to promptly restore the natural tissue anatomy and mechanical functions .
10-1	1481-1491	Biomedical	object[82]	giv[82]	coref	11-1[87_82]
10-2	1492-1501	scaffolds	object[82]	giv[82]	_	_
10-3	1502-1505	are	_	_	_	_
10-4	1506-1512	porous	_	_	_	_
10-5	1513-1514	,	_	_	_	_
10-6	1515-1526	implantable	substance[83]	new[83]	coref	22-9[230_83]
10-7	1527-1539	biomaterials	substance[83]	new[83]	_	_
10-8	1540-1541	,	_	_	_	_
10-9	1542-1548	shaped	_	_	_	_
10-10	1549-1551	to	_	_	_	_
10-11	1552-1560	promptly	_	_	_	_
10-12	1561-1568	restore	_	_	_	_
10-13	1569-1572	the	abstract[85]	new[85]	_	_
10-14	1573-1580	natural	abstract[85]	new[85]	_	_
10-15	1581-1587	tissue	object|abstract[85]	giv|new[85]	coref	12-26
10-16	1588-1595	anatomy	abstract[85]	new[85]	_	_
10-17	1596-1599	and	_	_	_	_
10-18	1600-1610	mechanical	abstract[86]	new[86]	coref	20-23[197_86]
10-19	1611-1620	functions	abstract[86]	new[86]	_	_
10-20	1621-1622	.	_	_	_	_

#Text=The scaffolds must also be capable of controlling foreign body reaction and new-tissue formation by targeted presentation and delivery of key molecules , e. g. , anti-inflammatory , growth factors , and proteins .
11-1	1623-1626	The	object[87]	giv[87]	coref	12-6[0_87]
11-2	1627-1636	scaffolds	object[87]	giv[87]	_	_
11-3	1637-1641	must	_	_	_	_
11-4	1642-1646	also	_	_	_	_
11-5	1647-1649	be	_	_	_	_
11-6	1650-1657	capable	_	_	_	_
11-7	1658-1660	of	_	_	_	_
11-8	1661-1672	controlling	_	_	_	_
11-9	1673-1680	foreign	abstract[89]	new[89]	_	_
11-10	1681-1685	body	organization|abstract[89]	giv|new[89]	coref	15-17[130_0]
11-11	1686-1694	reaction	abstract[89]	new[89]	_	_
11-12	1695-1698	and	_	_	_	_
11-13	1699-1709	new-tissue	abstract[90]	new[90]	_	_
11-14	1710-1719	formation	abstract[90]	new[90]	_	_
11-15	1720-1722	by	_	_	_	_
11-16	1723-1731	targeted	abstract[91]	new[91]	_	_
11-17	1732-1744	presentation	abstract[91]	new[91]	_	_
11-18	1745-1748	and	_	_	_	_
11-19	1749-1757	delivery	abstract[92]	new[92]	_	_
11-20	1758-1760	of	abstract[92]	new[92]	_	_
11-21	1761-1764	key	abstract[92]|substance[93]	new[92]|giv[93]	coref	12-3[98_93]
11-22	1765-1774	molecules	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-23	1775-1776	,	abstract[92]	new[92]	_	_
11-24	1777-1779	e.	abstract[92]|abstract[94]	new[92]|new[94]	_	_
11-25	1780-1782	g.	abstract[92]|abstract[94]	new[92]|new[94]	_	_
11-26	1783-1784	,	abstract[92]	new[92]	_	_
11-27	1785-1802	anti-inflammatory	abstract[92]	new[92]	_	_
11-28	1803-1804	,	abstract[92]	new[92]	_	_
11-29	1805-1811	growth	abstract[92]|abstract|abstract[96]	new[92]|giv|new[96]	coref|coref|coref|coref	18-26[178_0]|22-11[232_96]|18-26[178_0]|22-11[232_96]
11-30	1812-1819	factors	abstract[92]|abstract[96]	new[92]|new[96]	_	_
11-31	1820-1821	,	abstract[92]	new[92]	_	_
11-32	1822-1825	and	abstract[92]	new[92]	_	_
11-33	1826-1834	proteins	abstract[92]|substance	new[92]|new	_	_
11-34	1835-1836	.	_	_	_	_

#Text=Indeed , these molecules help scaffolds to reduce inflammation , recruit and direct differentiation of stem cells from surrounding tissues and ultimately , promote functional tissue integration in situ .
12-1	1837-1843	Indeed	_	_	_	_
12-2	1844-1845	,	_	_	_	_
12-3	1846-1851	these	substance[98]	giv[98]	coref	19-30[184_98]
12-4	1852-1861	molecules	substance[98]	giv[98]	_	_
12-5	1862-1866	help	_	_	_	_
12-6	1867-1876	scaffolds	object	giv	coref	13-1
12-7	1877-1879	to	_	_	_	_
12-8	1880-1886	reduce	_	_	_	_
12-9	1887-1899	inflammation	abstract	new	_	_
12-10	1900-1901	,	_	_	_	_
12-11	1902-1909	recruit	_	_	_	_
12-12	1910-1913	and	_	_	_	_
12-13	1914-1920	direct	abstract[101]	new[101]	_	_
12-14	1921-1936	differentiation	abstract[101]	new[101]	_	_
12-15	1937-1939	of	abstract[101]	new[101]	_	_
12-16	1940-1944	stem	abstract[101]|object[102]	new[101]|new[102]	coref	14-6[117_102]
12-17	1945-1950	cells	abstract[101]|object[102]	new[101]|new[102]	_	_
12-18	1951-1955	from	abstract[101]|object[102]	new[101]|new[102]	_	_
12-19	1956-1967	surrounding	abstract[101]|object[102]|object[103]	new[101]|new[102]|giv[103]	coref	14-2[116_103]
12-20	1968-1975	tissues	abstract[101]|object[102]|object[103]	new[101]|new[102]|giv[103]	_	_
12-21	1976-1979	and	abstract[101]|object[102]	new[101]|new[102]	_	_
12-22	1980-1990	ultimately	abstract[101]|object[102]	new[101]|new[102]	_	_
12-23	1991-1992	,	_	_	_	_
12-24	1993-2000	promote	_	_	_	_
12-25	2001-2011	functional	abstract[105]	giv[105]	_	_
12-26	2012-2018	tissue	object|abstract[105]	giv|giv[105]	coref	14-20
12-27	2019-2030	integration	abstract[105]	giv[105]	_	_
12-28	2031-2033	in	abstract[105]	giv[105]	_	_
12-29	2034-2038	situ	abstract[105]	giv[105]	_	_
12-30	2039-2040	.	_	_	_	_

#Text=Scaffolds design and fabrication have evolved greatly in the past twenty years due to the large knowledge accumulated on materials design , processing and characterization of cell/scaffold interactions .
13-1	2041-2050	Scaffolds	object|abstract[107]	giv|new[107]	coref|coref|coref|coref	13-20[112_107]|15-11|13-20[112_107]|15-11
13-2	2051-2057	design	abstract[107]	new[107]	_	_
13-3	2058-2061	and	_	_	_	_
13-4	2062-2073	fabrication	abstract	new	_	_
13-5	2074-2078	have	_	_	_	_
13-6	2079-2086	evolved	_	_	_	_
13-7	2087-2094	greatly	_	_	_	_
13-8	2095-2097	in	_	_	_	_
13-9	2098-2101	the	time[109]	new[109]	_	_
13-10	2102-2106	past	time[109]	new[109]	_	_
13-11	2107-2113	twenty	time[109]	new[109]	_	_
13-12	2114-2119	years	time[109]	new[109]	_	_
13-13	2120-2123	due	_	_	_	_
13-14	2124-2126	to	_	_	_	_
13-15	2127-2130	the	abstract[110]	new[110]	_	_
13-16	2131-2136	large	abstract[110]	new[110]	_	_
13-17	2137-2146	knowledge	abstract[110]	new[110]	_	_
13-18	2147-2158	accumulated	_	_	_	_
13-19	2159-2161	on	_	_	_	_
13-20	2162-2171	materials	substance|abstract[112]	new|giv[112]	coref|coref|coref|coref	17-1[163_0]|21-4[0_112]|17-1[163_0]|21-4[0_112]
13-21	2172-2178	design	abstract[112]	giv[112]	_	_
13-22	2179-2180	,	_	_	_	_
13-23	2181-2191	processing	abstract	new	coref	22-15
13-24	2192-2195	and	_	_	_	_
13-25	2196-2212	characterization	abstract[114]	new[114]	_	_
13-26	2213-2215	of	abstract[114]	new[114]	_	_
13-27	2216-2229	cell/scaffold	abstract[114]|abstract[115]	new[114]|new[115]	_	_
13-28	2230-2242	interactions	abstract[114]|abstract[115]	new[114]|new[115]	_	_
13-29	2243-2244	.	_	_	_	_

#Text=In the natural tissues , cells and extracellular matrix ( ECM ) organize into 3D structures from sub-cellular to tissue level .
14-1	2245-2247	In	_	_	_	_
14-2	2248-2251	the	object[116]	giv[116]	coref	15-5[124_116]
14-3	2252-2259	natural	object[116]	giv[116]	_	_
14-4	2260-2267	tissues	object[116]	giv[116]	_	_
14-5	2268-2269	,	_	_	_	_
14-6	2270-2275	cells	object[117]	giv[117]	coref	15-29[0_117]
14-7	2276-2279	and	object[117]	giv[117]	_	_
14-8	2280-2293	extracellular	object[117]|object[118]	giv[117]|new[118]	coref	19-35[186_118]
14-9	2294-2300	matrix	object[117]|object[118]	giv[117]|new[118]	_	_
14-10	2301-2302	(	_	_	_	_
14-11	2303-2306	ECM	place	new	coref	20-41[202_0]
14-12	2307-2308	)	_	_	_	_
14-13	2309-2317	organize	_	_	_	_
14-14	2318-2322	into	_	_	_	_
14-15	2323-2325	3D	abstract|abstract[121]	giv|new[121]	_	_
14-16	2326-2336	structures	abstract[121]	new[121]	_	_
14-17	2337-2341	from	_	_	_	_
14-18	2342-2354	sub-cellular	_	_	_	_
14-19	2355-2357	to	_	_	_	_
14-20	2358-2364	tissue	object|abstract[123]	giv|new[123]	coref|coref	15-34|15-34
14-21	2365-2370	level	abstract[123]	new[123]	_	_
14-22	2371-2372	.	_	_	_	_

#Text=Consequently , to engineer functional tissues and organs successfully , scaffolds must capture the essence of this cells/ECM organization and must provide a porous structure able to facilitate cells distribution and guide 3D tissue regeneration .
15-1	2373-2385	Consequently	_	_	_	_
15-2	2386-2387	,	_	_	_	_
15-3	2388-2390	to	_	_	_	_
15-4	2391-2399	engineer	_	_	_	_
15-5	2400-2410	functional	object[124]|object[125]	giv[124]|giv[125]	coref|coref	24-23[250_124]|24-23[250_124]
15-6	2411-2418	tissues	object[124]|object[125]	giv[124]|giv[125]	_	_
15-7	2419-2422	and	object[125]	giv[125]	_	_
15-8	2423-2429	organs	object[125]|object	giv[125]|giv	_	_
15-9	2430-2442	successfully	_	_	_	_
15-10	2443-2444	,	_	_	_	_
15-11	2445-2454	scaffolds	object	giv	coref	16-1
15-12	2455-2459	must	_	_	_	_
15-13	2460-2467	capture	_	_	_	_
15-14	2468-2471	the	abstract[128]	new[128]	_	_
15-15	2472-2479	essence	abstract[128]	new[128]	_	_
15-16	2480-2482	of	abstract[128]	new[128]	_	_
15-17	2483-2487	this	abstract[128]|abstract[130]	new[128]|giv[130]	coref	16-44[0_130]
15-18	2488-2497	cells/ECM	abstract[128]|abstract|abstract[130]	new[128]|new|giv[130]	_	_
15-19	2498-2510	organization	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
15-20	2511-2514	and	_	_	_	_
15-21	2515-2519	must	_	_	_	_
15-22	2520-2527	provide	_	_	_	_
15-23	2528-2529	a	abstract[131]	new[131]	ana	17-35[0_131]
15-24	2530-2536	porous	abstract[131]	new[131]	_	_
15-25	2537-2546	structure	abstract[131]	new[131]	_	_
15-26	2547-2551	able	_	_	_	_
15-27	2552-2554	to	_	_	_	_
15-28	2555-2565	facilitate	_	_	_	_
15-29	2566-2571	cells	object|abstract[133]	giv|new[133]	coref|coref	16-35|16-35
15-30	2572-2584	distribution	abstract[133]	new[133]	_	_
15-31	2585-2588	and	_	_	_	_
15-32	2589-2594	guide	_	_	_	_
15-33	2595-2597	3D	abstract[135]	new[135]	_	_
15-34	2598-2604	tissue	object|abstract[135]	giv|new[135]	coref	17-29[170_0]
15-35	2605-2617	regeneration	abstract[135]	new[135]	_	_
15-36	2618-2619	.	_	_	_	_

#Text=Scaffolds pore size and shape , pore wall morphology , porosity , surface area and pore interconnectivity , are probably the most important architectural parameters , as they have been shown to directly impact cells migration and colonization , new ECM biosynthesis and organization , oxygen and nutrients transport to cells , as well as metabolic wastes removal in the whole cell/scaffold construct .
16-1	2620-2629	Scaffolds	object|abstract[138]	giv|new[138]	coref|coref	19-10[180_0]|19-10[180_0]
16-2	2630-2634	pore	abstract|abstract[138]	new|new[138]	coref	16-7
16-3	2635-2639	size	abstract[138]	new[138]	_	_
16-4	2640-2643	and	_	_	_	_
16-5	2644-2649	shape	abstract	new	_	_
16-6	2650-2651	,	_	_	_	_
16-7	2652-2656	pore	object|person[142]	giv|new[142]	coref|coref	16-16|16-16
16-8	2657-2661	wall	object|person[142]	new|new[142]	_	_
16-9	2662-2672	morphology	person[142]	new[142]	_	_
16-10	2673-2674	,	_	_	_	_
16-11	2675-2683	porosity	abstract	new	_	_
16-12	2684-2685	,	_	_	_	_
16-13	2686-2693	surface	place|abstract[145]	new|new[145]	_	_
16-14	2694-2698	area	abstract[145]	new[145]	_	_
16-15	2699-2702	and	_	_	_	_
16-16	2703-2707	pore	abstract|abstract[147]	giv|new[147]	coref|coref	16-20[148_147]|16-20[148_147]
16-17	2708-2725	interconnectivity	abstract[147]	new[147]	_	_
16-18	2726-2727	,	_	_	_	_
16-19	2728-2731	are	_	_	_	_
16-20	2732-2740	probably	abstract[148]	giv[148]	ana	16-28[0_148]
16-21	2741-2744	the	abstract[148]	giv[148]	_	_
16-22	2745-2749	most	abstract[148]	giv[148]	_	_
16-23	2750-2759	important	abstract[148]	giv[148]	_	_
16-24	2760-2773	architectural	abstract[148]	giv[148]	_	_
16-25	2774-2784	parameters	abstract[148]	giv[148]	_	_
16-26	2785-2786	,	_	_	_	_
16-27	2787-2789	as	_	_	_	_
16-28	2790-2794	they	object	giv	coref	23-10
16-29	2795-2799	have	_	_	_	_
16-30	2800-2804	been	_	_	_	_
16-31	2805-2810	shown	_	_	_	_
16-32	2811-2813	to	_	_	_	_
16-33	2814-2822	directly	_	_	_	_
16-34	2823-2829	impact	_	_	_	_
16-35	2830-2835	cells	object|abstract[151]	giv|new[151]	coref|coref	16-51|16-51
16-36	2836-2845	migration	abstract[151]	new[151]	_	_
16-37	2846-2849	and	_	_	_	_
16-38	2850-2862	colonization	event	new	_	_
16-39	2863-2864	,	_	_	_	_
16-40	2865-2868	new	abstract[153]	new[153]	coref	20-38[201_153]
16-41	2869-2872	ECM	abstract[153]	new[153]	_	_
16-42	2873-2885	biosynthesis	abstract[153]	new[153]	_	_
16-43	2886-2889	and	_	_	_	_
16-44	2890-2902	organization	abstract	giv	_	_
16-45	2903-2904	,	_	_	_	_
16-46	2905-2911	oxygen	substance	new	_	_
16-47	2912-2915	and	_	_	_	_
16-48	2916-2925	nutrients	substance|abstract[157]	new|new[157]	_	_
16-49	2926-2935	transport	abstract[157]	new[157]	_	_
16-50	2936-2938	to	abstract[157]	new[157]	_	_
16-51	2939-2944	cells	abstract[157]|object	new[157]|giv	coref	19-42
16-52	2945-2946	,	_	_	_	_
16-53	2947-2949	as	_	_	_	_
16-54	2950-2954	well	_	_	_	_
16-55	2955-2957	as	_	_	_	_
16-56	2958-2967	metabolic	abstract[160]	new[160]	_	_
16-57	2968-2974	wastes	substance|abstract[160]	new|new[160]	_	_
16-58	2975-2982	removal	abstract[160]	new[160]	_	_
16-59	2983-2985	in	abstract[160]	new[160]	_	_
16-60	2986-2989	the	abstract[160]|abstract[161]	new[160]|new[161]	_	_
16-61	2990-2995	whole	abstract[160]|abstract[161]	new[160]|new[161]	_	_
16-62	2996-3009	cell/scaffold	abstract[160]|abstract[161]	new[160]|new[161]	_	_
16-63	3010-3019	construct	abstract[160]|abstract[161]	new[160]|new[161]	_	_
16-64	3020-3021	.	_	_	_	_

#Text=The scaffold material must be selected and/or designed with a degradation and resorption rate such that scaffold strength is retained until the tissue-engineered transplant is fully remodeled by the host tissue and can assume its own structural role .
17-1	3022-3025	The	substance[163]	giv[163]	_	_
17-2	3026-3034	scaffold	object|substance[163]	new|giv[163]	coref	17-17
17-3	3035-3043	material	substance[163]	giv[163]	_	_
17-4	3044-3048	must	_	_	_	_
17-5	3049-3051	be	_	_	_	_
17-6	3052-3060	selected	_	_	_	_
17-7	3061-3067	and/or	_	_	_	_
17-8	3068-3076	designed	_	_	_	_
17-9	3077-3081	with	_	_	_	_
17-10	3082-3083	a	abstract[164]	new[164]	_	_
17-11	3084-3095	degradation	abstract[164]	new[164]	_	_
17-12	3096-3099	and	_	_	_	_
17-13	3100-3110	resorption	abstract|abstract[166]	new|new[166]	_	_
17-14	3111-3115	rate	abstract[166]	new[166]	_	_
17-15	3116-3120	such	_	_	_	_
17-16	3121-3125	that	_	_	_	_
17-17	3126-3134	scaffold	object|abstract[168]	giv|new[168]	coref|coref	21-25|21-25
17-18	3135-3143	strength	abstract[168]	new[168]	_	_
17-19	3144-3146	is	_	_	_	_
17-20	3147-3155	retained	_	_	_	_
17-21	3156-3161	until	_	_	_	_
17-22	3162-3165	the	object[169]	new[169]	_	_
17-23	3166-3183	tissue-engineered	object[169]	new[169]	_	_
17-24	3184-3194	transplant	object[169]	new[169]	_	_
17-25	3195-3197	is	_	_	_	_
17-26	3198-3203	fully	_	_	_	_
17-27	3204-3213	remodeled	_	_	_	_
17-28	3214-3216	by	_	_	_	_
17-29	3217-3220	the	object[170]	giv[170]	coref	18-26[0_170]
17-30	3221-3225	host	object[170]	giv[170]	_	_
17-31	3226-3232	tissue	object[170]	giv[170]	_	_
17-32	3233-3236	and	_	_	_	_
17-33	3237-3240	can	_	_	_	_
17-34	3241-3247	assume	_	_	_	_
17-35	3248-3251	its	abstract|abstract[172]	giv|new[172]	coref|coref	21-29[216_0]|21-29[216_0]
17-36	3252-3255	own	abstract[172]	new[172]	_	_
17-37	3256-3266	structural	abstract[172]	new[172]	_	_
17-38	3267-3271	role	abstract[172]	new[172]	_	_
17-39	3272-3273	.	_	_	_	_

#Text=More importantly , controlling mechanical properties at cellular and sub-cellular levels is important to emulate as closely as possible the in vivo cell behavior and tissue growth .
18-1	3274-3278	More	_	_	_	_
18-2	3279-3290	importantly	_	_	_	_
18-3	3291-3292	,	_	_	_	_
18-4	3293-3304	controlling	_	_	_	_
18-5	3305-3315	mechanical	abstract[173]	new[173]	coref	19-4[179_173]
18-6	3316-3326	properties	abstract[173]	new[173]	_	_
18-7	3327-3329	at	_	_	_	_
18-8	3330-3338	cellular	abstract[174]	new[174]	_	_
18-9	3339-3342	and	abstract[174]	new[174]	_	_
18-10	3343-3355	sub-cellular	abstract[174]	new[174]	_	_
18-11	3356-3362	levels	abstract[174]	new[174]	_	_
18-12	3363-3365	is	_	_	_	_
18-13	3366-3375	important	_	_	_	_
18-14	3376-3378	to	_	_	_	_
18-15	3379-3386	emulate	_	_	_	_
18-16	3387-3389	as	_	_	_	_
18-17	3390-3397	closely	_	_	_	_
18-18	3398-3400	as	_	_	_	_
18-19	3401-3409	possible	_	_	_	_
18-20	3410-3413	the	abstract[176]	new[176]	coref	19-42[188_176]
18-21	3414-3416	in	abstract[176]	new[176]	_	_
18-22	3417-3421	vivo	abstract[176]	new[176]	_	_
18-23	3422-3426	cell	place|abstract[176]	new|new[176]	_	_
18-24	3427-3435	behavior	abstract[176]	new[176]	_	_
18-25	3436-3439	and	_	_	_	_
18-26	3440-3446	tissue	object|abstract[178]	giv|giv[178]	coref|coref|coref|coref	20-48|20-45[204_178]|20-48|20-45[204_178]
18-27	3447-3453	growth	abstract[178]	giv[178]	_	_
18-28	3454-3455	.	_	_	_	_

#Text=Nevertheless , controlling the morphological and biomechanical properties of porous scaffolds is not enough for the success of scaffolds-based therapies , as there is also the need to load matricellular and soluble molecules inside scaffolds ’ matrix as biochemical regulators of cells behavior .
19-1	3456-3468	Nevertheless	_	_	_	_
19-2	3469-3470	,	_	_	_	_
19-3	3471-3482	controlling	_	_	_	_
19-4	3483-3486	the	abstract[179]	giv[179]	coref	24-36[253_179]
19-5	3487-3500	morphological	abstract[179]	giv[179]	_	_
19-6	3501-3504	and	abstract[179]	giv[179]	_	_
19-7	3505-3518	biomechanical	abstract[179]	giv[179]	_	_
19-8	3519-3529	properties	abstract[179]	giv[179]	_	_
19-9	3530-3532	of	abstract[179]	giv[179]	_	_
19-10	3533-3539	porous	abstract[179]|object[180]	giv[179]|giv[180]	coref	19-35[185_180]
19-11	3540-3549	scaffolds	abstract[179]|object[180]	giv[179]|giv[180]	_	_
19-12	3550-3552	is	_	_	_	_
19-13	3553-3556	not	_	_	_	_
19-14	3557-3563	enough	_	_	_	_
19-15	3564-3567	for	_	_	_	_
19-16	3568-3571	the	abstract[181]	new[181]	_	_
19-17	3572-3579	success	abstract[181]	new[181]	_	_
19-18	3580-3582	of	abstract[181]	new[181]	_	_
19-19	3583-3598	scaffolds-based	abstract[181]|abstract[182]	new[181]|new[182]	_	_
19-20	3599-3608	therapies	abstract[181]|abstract[182]	new[181]|new[182]	_	_
19-21	3609-3610	,	_	_	_	_
19-22	3611-3613	as	_	_	_	_
19-23	3614-3619	there	_	_	_	_
19-24	3620-3622	is	_	_	_	_
19-25	3623-3627	also	_	_	_	_
19-26	3628-3631	the	abstract[183]	giv[183]	_	_
19-27	3632-3636	need	abstract[183]	giv[183]	_	_
19-28	3637-3639	to	_	_	_	_
19-29	3640-3644	load	_	_	_	_
19-30	3645-3658	matricellular	substance[184]	giv[184]	_	_
19-31	3659-3662	and	substance[184]	giv[184]	_	_
19-32	3663-3670	soluble	substance[184]	giv[184]	_	_
19-33	3671-3680	molecules	substance[184]	giv[184]	_	_
19-34	3681-3687	inside	_	_	_	_
19-35	3688-3697	scaffolds	object[185]|object[186]	giv[185]|giv[186]	coref|coref	20-7[190_185]|20-7[190_185]
19-36	3698-3699	’	object[185]|object[186]	giv[185]|giv[186]	_	_
19-37	3700-3706	matrix	object[186]	giv[186]	_	_
19-38	3707-3709	as	object[186]	giv[186]	_	_
19-39	3710-3721	biochemical	object[186]	giv[186]	_	_
19-40	3722-3732	regulators	object[186]	giv[186]	_	_
19-41	3733-3735	of	object[186]	giv[186]	_	_
19-42	3736-3741	cells	object[186]|object|abstract[188]	giv[186]|giv|giv[188]	ana|coref|ana|coref	20-3[0_188]|20-23[196_0]|20-3[0_188]|20-23[196_0]
19-43	3742-3750	behavior	object[186]|abstract[188]	giv[186]|giv[188]	_	_
19-44	3751-3752	.	_	_	_	_

#Text=Indeed , it is reported that porous scaffolds releasing biochemical signals following a precise dose and time intervals to target sites stimulate cells ’ functions ( e. g. , adhesion , proliferation and migration ) , promote the biosynthesis of new ECM and , ultimately , guide tissue growth , morphogenesis and vascularization .
20-1	3753-3759	Indeed	_	_	_	_
20-2	3760-3761	,	_	_	_	_
20-3	3762-3764	it	abstract	giv	_	_
20-4	3765-3767	is	_	_	_	_
20-5	3768-3776	reported	_	_	_	_
20-6	3777-3781	that	_	_	_	_
20-7	3782-3788	porous	object[190]	giv[190]	coref	21-2[207_190]
20-8	3789-3798	scaffolds	object[190]	giv[190]	_	_
20-9	3799-3808	releasing	_	_	_	_
20-10	3809-3820	biochemical	abstract[191]	new[191]	_	_
20-11	3821-3828	signals	abstract[191]	new[191]	_	_
20-12	3829-3838	following	_	_	_	_
20-13	3839-3840	a	quantity[192]	new[192]	_	_
20-14	3841-3848	precise	quantity[192]	new[192]	_	_
20-15	3849-3853	dose	quantity[192]	new[192]	_	_
20-16	3854-3857	and	_	_	_	_
20-17	3858-3862	time	time|time[194]	new|new[194]	_	_
20-18	3863-3872	intervals	time[194]	new[194]	_	_
20-19	3873-3875	to	_	_	_	_
20-20	3876-3882	target	_	_	_	_
20-21	3883-3888	sites	place	new	_	_
20-22	3889-3898	stimulate	_	_	_	_
20-23	3899-3904	cells	object[196]|event[197]	giv[196]|giv[197]	appos|coref|appos|coref	20-30[0_197]|21-46[220_196]|20-30[0_197]|21-46[220_196]
20-24	3905-3906	’	object[196]|event[197]	giv[196]|giv[197]	_	_
20-25	3907-3916	functions	event[197]	giv[197]	_	_
20-26	3917-3918	(	_	_	_	_
20-27	3919-3921	e.	_	_	_	_
20-28	3922-3924	g.	_	_	_	_
20-29	3925-3926	,	_	_	_	_
20-30	3927-3935	adhesion	abstract	giv	appos	20-32
20-31	3936-3937	,	_	_	_	_
20-32	3938-3951	proliferation	event	giv	appos	20-34
20-33	3952-3955	and	_	_	_	_
20-34	3956-3965	migration	event	giv	_	_
20-35	3966-3967	)	_	_	_	_
20-36	3968-3969	,	_	_	_	_
20-37	3970-3977	promote	_	_	_	_
20-38	3978-3981	the	abstract[201]	giv[201]	_	_
20-39	3982-3994	biosynthesis	abstract[201]	giv[201]	_	_
20-40	3995-3997	of	abstract[201]	giv[201]	_	_
20-41	3998-4001	new	abstract[201]|place[202]	giv[201]|giv[202]	coref	21-30[0_202]
20-42	4002-4005	ECM	abstract[201]|place[202]	giv[201]|giv[202]	_	_
20-43	4006-4009	and	abstract[201]	giv[201]	_	_
20-44	4010-4011	,	abstract[201]	giv[201]	_	_
20-45	4012-4022	ultimately	abstract[201]|abstract[204]	giv[201]|giv[204]	coref	21-46[221_204]
20-46	4023-4024	,	abstract[201]|abstract[204]	giv[201]|giv[204]	_	_
20-47	4025-4030	guide	abstract[201]|abstract[204]	giv[201]|giv[204]	_	_
20-48	4031-4037	tissue	abstract[201]|object|abstract[204]	giv[201]|giv|giv[204]	coref	21-50
20-49	4038-4044	growth	abstract[201]|abstract[204]	giv[201]|giv[204]	_	_
20-50	4045-4046	,	abstract[201]	giv[201]	_	_
20-51	4047-4060	morphogenesis	abstract[201]|abstract	giv[201]|new	coref	21-50[223_0]
20-52	4061-4064	and	abstract[201]	giv[201]	_	_
20-53	4065-4080	vascularization	abstract[201]|abstract	giv[201]|new	_	_
20-54	4081-4082	.	_	_	_	_

#Text=Increasing scaffolds ’ design complexity is therefore extremely demanding and scientists face some important challenges , such as : ( 1 ) engineering of scaffold microarchitecture to mimic the ECM structure , ( 2 ) imprinting topological and biochemical patterns inside scaffolds pores to guide cells ’ growth and tissue morphogenesis , and ( 3 ) developing automated processes for the precise and reliable control of scaffolds ’ features and geometry .
21-1	4083-4093	Increasing	_	_	_	_
21-2	4094-4103	scaffolds	object[207]|abstract[209]	giv[207]|new[209]	coref|coref	21-42[0_207]|21-42[0_207]
21-3	4104-4105	’	object[207]|abstract[209]	giv[207]|new[209]	_	_
21-4	4106-4112	design	abstract|abstract[209]	giv|new[209]	_	_
21-5	4113-4123	complexity	abstract[209]	new[209]	_	_
21-6	4124-4126	is	_	_	_	_
21-7	4127-4136	therefore	_	_	_	_
21-8	4137-4146	extremely	_	_	_	_
21-9	4147-4156	demanding	_	_	_	_
21-10	4157-4160	and	_	_	_	_
21-11	4161-4171	scientists	person	new	_	_
21-12	4172-4176	face	_	_	_	_
21-13	4177-4181	some	abstract[211]	new[211]	_	_
21-14	4182-4191	important	abstract[211]	new[211]	_	_
21-15	4192-4202	challenges	abstract[211]	new[211]	_	_
21-16	4203-4204	,	abstract[211]	new[211]	_	_
21-17	4205-4209	such	abstract[211]	new[211]	_	_
21-18	4210-4212	as	abstract[211]	new[211]	_	_
21-19	4213-4214	:	abstract[211]	new[211]	_	_
21-20	4215-4216	(	abstract[211]	new[211]	_	_
21-21	4217-4218	1	abstract[211]	new[211]	_	_
21-22	4219-4220	)	abstract[211]	new[211]	_	_
21-23	4221-4232	engineering	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
21-24	4233-4235	of	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
21-25	4236-4244	scaffold	abstract[211]|abstract[212]|object|object[214]	new[211]|giv[212]|giv|new[214]	_	_
21-26	4245-4262	microarchitecture	abstract[211]|abstract[212]|object[214]	new[211]|giv[212]|new[214]	_	_
21-27	4263-4265	to	_	_	_	_
21-28	4266-4271	mimic	_	_	_	_
21-29	4272-4275	the	abstract[216]	giv[216]	_	_
21-30	4276-4279	ECM	place|abstract[216]	giv|giv[216]	coref	24-18[249_0]
21-31	4280-4289	structure	abstract[216]	giv[216]	_	_
21-32	4290-4291	,	abstract[216]	giv[216]	_	_
21-33	4292-4293	(	abstract[216]	giv[216]	_	_
21-34	4294-4295	2	abstract[216]	giv[216]	_	_
21-35	4296-4297	)	abstract[216]	giv[216]	_	_
21-36	4298-4308	imprinting	_	_	_	_
21-37	4309-4320	topological	abstract[217]	new[217]	_	_
21-38	4321-4324	and	abstract[217]	new[217]	_	_
21-39	4325-4336	biochemical	abstract[217]	new[217]	_	_
21-40	4337-4345	patterns	abstract[217]	new[217]	_	_
21-41	4346-4352	inside	abstract[217]	new[217]	_	_
21-42	4353-4362	scaffolds	abstract[217]|object|object[219]	new[217]|giv|new[219]	coref|coref	21-67[226_0]|21-67[226_0]
21-43	4363-4368	pores	abstract[217]|object[219]	new[217]|new[219]	_	_
21-44	4369-4371	to	_	_	_	_
21-45	4372-4377	guide	_	_	_	_
21-46	4378-4383	cells	object[220]|abstract[221]	giv[220]|giv[221]	coref|coref	22-11[0_221]|22-11[0_221]
21-47	4384-4385	’	object[220]|abstract[221]	giv[220]|giv[221]	_	_
21-48	4386-4392	growth	abstract[221]	giv[221]	_	_
21-49	4393-4396	and	_	_	_	_
21-50	4397-4403	tissue	object|abstract[223]	giv|giv[223]	_	_
21-51	4404-4417	morphogenesis	abstract[223]	giv[223]	_	_
21-52	4418-4419	,	_	_	_	_
21-53	4420-4423	and	_	_	_	_
21-54	4424-4425	(	_	_	_	_
21-55	4426-4427	3	_	_	_	_
21-56	4428-4429	)	_	_	_	_
21-57	4430-4440	developing	_	_	_	_
21-58	4441-4450	automated	abstract[224]	new[224]	_	_
21-59	4451-4460	processes	abstract[224]	new[224]	_	_
21-60	4461-4464	for	abstract[224]	new[224]	_	_
21-61	4465-4468	the	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-62	4469-4476	precise	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-63	4477-4480	and	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-64	4481-4489	reliable	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-65	4490-4497	control	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-66	4498-4500	of	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-67	4501-4510	scaffolds	abstract[224]|abstract[225]|object[226]|abstract[227]	new[224]|new[225]|giv[226]|new[227]	coref|coref	22-1[229_226]|22-1[229_226]
21-68	4511-4512	’	abstract[224]|abstract[225]|object[226]|abstract[227]	new[224]|new[225]|giv[226]|new[227]	_	_
21-69	4513-4521	features	abstract[224]|abstract[225]|abstract[227]	new[224]|new[225]|new[227]	_	_
21-70	4522-4525	and	abstract[224]|abstract[225]	new[224]|new[225]	_	_
21-71	4526-4534	geometry	abstract[224]|abstract[225]|abstract	new[224]|new[225]|new	_	_
21-72	4535-4536	.	_	_	_	_

#Text=Porous bioactive scaffolds can be fabricated by combining biomaterials and growth factors through different processing techniques .
22-1	4537-4543	Porous	object[229]	giv[229]	coref	24-9[0_229]
22-2	4544-4553	bioactive	object[229]	giv[229]	_	_
22-3	4554-4563	scaffolds	object[229]	giv[229]	_	_
22-4	4564-4567	can	_	_	_	_
22-5	4568-4570	be	_	_	_	_
22-6	4571-4581	fabricated	_	_	_	_
22-7	4582-4584	by	_	_	_	_
22-8	4585-4594	combining	_	_	_	_
22-9	4595-4607	biomaterials	substance[230]	giv[230]	_	_
22-10	4608-4611	and	substance[230]	giv[230]	_	_
22-11	4612-4618	growth	substance[230]|abstract|substance[232]	giv[230]|giv|giv[232]	_	_
22-12	4619-4626	factors	substance[230]|substance[232]	giv[230]|giv[232]	_	_
22-13	4627-4634	through	_	_	_	_
22-14	4635-4644	different	abstract[234]	new[234]	_	_
22-15	4645-4655	processing	abstract|abstract[234]	giv|new[234]	_	_
22-16	4656-4666	techniques	abstract[234]	new[234]	_	_
22-17	4667-4668	.	_	_	_	_

#Text=This review focuses the attention on modular approaches where samples are built by the “ bottom-up ” assembly of smaller units or “ modules ” , each one specifically designed for distinct tasks .
23-1	4669-4673	This	event[235]	new[235]	_	_
23-2	4674-4680	review	event[235]	new[235]	_	_
23-3	4681-4688	focuses	_	_	_	_
23-4	4689-4692	the	abstract[236]	new[236]	_	_
23-5	4693-4702	attention	abstract[236]	new[236]	_	_
23-6	4703-4705	on	abstract[236]	new[236]	_	_
23-7	4706-4713	modular	abstract[236]|abstract[237]	new[236]|new[237]	coref	24-3[0_237]
23-8	4714-4724	approaches	abstract[236]|abstract[237]	new[236]|new[237]	_	_
23-9	4725-4730	where	_	_	_	_
23-10	4731-4738	samples	object	giv	_	_
23-11	4739-4742	are	_	_	_	_
23-12	4743-4748	built	_	_	_	_
23-13	4749-4751	by	_	_	_	_
23-14	4752-4755	the	organization[240]	new[240]	_	_
23-15	4756-4757	“	organization[240]	new[240]	_	_
23-16	4758-4767	bottom-up	abstract|organization[240]	new|new[240]	_	_
23-17	4768-4769	”	organization[240]	new[240]	_	_
23-18	4770-4778	assembly	organization[240]	new[240]	_	_
23-19	4779-4781	of	organization[240]	new[240]	_	_
23-20	4782-4789	smaller	organization[240]|object[241]	new[240]|new[241]	_	_
23-21	4790-4795	units	organization[240]|object[241]	new[240]|new[241]	_	_
23-22	4796-4798	or	organization[240]	new[240]	_	_
23-23	4799-4800	“	organization[240]	new[240]	_	_
23-24	4801-4808	modules	organization[240]|place	new[240]|new	coref	24-31[252_0]
23-25	4809-4810	”	organization[240]	new[240]	_	_
23-26	4811-4812	,	_	_	_	_
23-27	4813-4817	each	object[243]	new[243]	_	_
23-28	4818-4821	one	object[243]	new[243]	_	_
23-29	4822-4834	specifically	_	_	_	_
23-30	4835-4843	designed	_	_	_	_
23-31	4844-4847	for	_	_	_	_
23-32	4848-4856	distinct	abstract[244]	new[244]	_	_
23-33	4857-4862	tasks	abstract[244]	new[244]	_	_
23-34	4863-4864	.	_	_	_	_

#Text=Bottom up approaches have the potential to build scaffolds mimicking the complex molecular and structural microenvironment of the native ECM of every kind of tissues by the proper assembly of micro- and nano-structured modules with well-defined morphological and biochemical properties .
24-1	4865-4871	Bottom	_	_	_	_
24-2	4872-4874	up	_	_	_	_
24-3	4875-4885	approaches	abstract	giv	_	_
24-4	4886-4890	have	_	_	_	_
24-5	4891-4894	the	abstract[246]	new[246]	_	_
24-6	4895-4904	potential	abstract[246]	new[246]	_	_
24-7	4905-4907	to	_	_	_	_
24-8	4908-4913	build	_	_	_	_
24-9	4914-4923	scaffolds	object	giv	_	_
24-10	4924-4933	mimicking	_	_	_	_
24-11	4934-4937	the	abstract[248]	new[248]	_	_
24-12	4938-4945	complex	abstract[248]	new[248]	_	_
24-13	4946-4955	molecular	abstract[248]	new[248]	_	_
24-14	4956-4959	and	abstract[248]	new[248]	_	_
24-15	4960-4970	structural	abstract[248]	new[248]	_	_
24-16	4971-4987	microenvironment	abstract[248]	new[248]	_	_
24-17	4988-4990	of	abstract[248]	new[248]	_	_
24-18	4991-4994	the	abstract[248]|place[249]	new[248]|giv[249]	_	_
24-19	4995-5001	native	abstract[248]|place[249]	new[248]|giv[249]	_	_
24-20	5002-5005	ECM	abstract[248]|place[249]	new[248]|giv[249]	_	_
24-21	5006-5008	of	abstract[248]|place[249]	new[248]|giv[249]	_	_
24-22	5009-5014	every	abstract[248]|place[249]	new[248]|giv[249]	_	_
24-23	5015-5019	kind	abstract[248]|place[249]|object[250]	new[248]|giv[249]|giv[250]	_	_
24-24	5020-5022	of	abstract[248]|place[249]|object[250]	new[248]|giv[249]|giv[250]	_	_
24-25	5023-5030	tissues	abstract[248]|place[249]|object[250]	new[248]|giv[249]|giv[250]	_	_
24-26	5031-5033	by	abstract[248]|place[249]	new[248]|giv[249]	_	_
24-27	5034-5037	the	abstract[248]|place[249]|abstract[251]	new[248]|giv[249]|new[251]	_	_
24-28	5038-5044	proper	abstract[248]|place[249]|abstract[251]	new[248]|giv[249]|new[251]	_	_
24-29	5045-5053	assembly	abstract[248]|place[249]|abstract[251]	new[248]|giv[249]|new[251]	_	_
24-30	5054-5056	of	abstract[248]|place[249]|abstract[251]	new[248]|giv[249]|new[251]	_	_
24-31	5057-5063	micro-	abstract[248]|place[249]|abstract[251]|place[252]	new[248]|giv[249]|new[251]|giv[252]	_	_
24-32	5064-5067	and	abstract[248]|place[249]|abstract[251]|place[252]	new[248]|giv[249]|new[251]|giv[252]	_	_
24-33	5068-5083	nano-structured	abstract[248]|place[249]|abstract[251]|place[252]	new[248]|giv[249]|new[251]|giv[252]	_	_
24-34	5084-5091	modules	abstract[248]|place[249]|abstract[251]|place[252]	new[248]|giv[249]|new[251]|giv[252]	_	_
24-35	5092-5096	with	abstract[248]|place[249]|abstract[251]|place[252]	new[248]|giv[249]|new[251]|giv[252]	_	_
24-36	5097-5109	well-defined	abstract[248]|place[249]|abstract[251]|place[252]|abstract[253]	new[248]|giv[249]|new[251]|giv[252]|giv[253]	_	_
24-37	5110-5123	morphological	abstract[248]|place[249]|abstract[251]|place[252]|abstract[253]	new[248]|giv[249]|new[251]|giv[252]|giv[253]	_	_
24-38	5124-5127	and	abstract[248]|place[249]|abstract[251]|place[252]|abstract[253]	new[248]|giv[249]|new[251]|giv[252]|giv[253]	_	_
24-39	5128-5139	biochemical	abstract[248]|place[249]|abstract[251]|place[252]|abstract[253]	new[248]|giv[249]|new[251]|giv[252]|giv[253]	_	_
24-40	5140-5150	properties	abstract[248]|place[249]|abstract[251]|place[252]|abstract[253]	new[248]|giv[249]|new[251]|giv[252]|giv[253]	_	_
24-41	5151-5152	.	_	_	_	_
